Log in

Relevant bibliographies by topics / Pustulose palmoplantaire / Journal articles

To see the other types of publications on this topic, follow the link: Pustulose palmoplantaire.

Journal articles on the topic 'Pustulose palmoplantaire'

Author: Grafiati

Published: 4 June 2021

Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Pustulose palmoplantaire.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Marsan, F. M., S. Hiret, M. Saint Jean, and L. Peuvrel. "Pustulose palmoplantaire unilatérale sous avélumab." Annales de Dermatologie et de Vénéréologie 146, no. 12 (2019): A152—A153. http://dx.doi.org/10.1016/j.annder.2019.09.198.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Danion, F., E. Bui, P. Riegel, et al. "Pustulose palmoplantaire fébrile au retour d’Ibiza." La Revue de Médecine Interne 32 (December 2011): S336—S337. http://dx.doi.org/10.1016/j.revmed.2011.10.061.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Obeid, G., G. Do-Pham, E. Sbidian, and L. Le Cleach. "Interventions dans la pustulose palmoplantaire : revue systématique Cochrane." Annales de Dermatologie et de Vénéréologie 145, no. 12 (2018): S131. http://dx.doi.org/10.1016/j.annder.2018.09.150.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

EL Bez, I., D. Ben Sellem, I. Slim, et al. "Acnée et pustulose palmoplantaire : pensez au syndrome Sapho." Annales de Dermatologie et de Vénéréologie 140 (April 2013): S55. http://dx.doi.org/10.1016/j.annder.2013.01.052.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Razera, Fernanda, Gislaine Silveira Olm, and Renan Rangel Bonamigo. "Dermatoses neutrofílicas: parte II." Anais Brasileiros de Dermatologia 86, no. 2 (2011): 195–211. http://dx.doi.org/10.1590/s0365-05962011000200001.

Full text

Abstract:

Neste artigo são abordadas as dermatoses neutrofílicas, complementando o artigo anterior (parte I). São apresentadas e comentadas as seguintes dermatoses: pustulose subcórnea de Sneddon-Wilkinson, dermatite crural pustulosa e atrófica, pustulose exantemática generalizada aguda, acroder matite contínua de Hallopeau, pustulose palmoplantar, acropustulose infantil, bacteride pustular de Andrews e foliculite pustulosa eosinofílica. Uma breve revisão das dermatoses neutrofílicas em pacientes pediátricos também é realizada.

APA, Harvard, Vancouver, ISO, and other styles

6

Rueda-Gotor, Javier, Miguel A. González-Gay, Ricardo Blanco, Carmen Gonzalez-Vela, Cristina Lopez-Obregon та Marcos A. González-López. "Effet bénéfique du tocilizumab dans la pustulose palmoplantaire induite par anti-TNF-α au cours de la polyarthrite rhumatoïde". Revue du Rhumatisme 79, № 5 (2012): 469–72. http://dx.doi.org/10.1016/j.rhum.2012.08.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Dantas, Aline Rodrigues, Wollia Monik Vaz Fernandes, Edilberto Vasconcelos Pereira Júnior, and Nicole Rangely Nogueira Martins De Carvalho. "Psoríase pustulosa palmoplantar na infância: um relato de caso." Revista de Patologia do Tocantins 4, no. 3 (2017): 43. http://dx.doi.org/10.20873/uft.2446-6492.2017v4n3p43.

Full text

Abstract:

Introdução: A psoríase pustulosa palmoplantar, também conhecida como pustulose palmoplantar (PPP) é uma forma de dermatose psoriasiforme caracterizada por erupções de pústulas estéreis de localização palmoplantar e simétrica. Sua prevalência é estimada entre 0,01 a 0,05%, afetando principalmente adultos do sexo feminino entre a sexta e a sétima décadas de vida. A doença é rara na faixa etária pediátrica. Desenvolvimento: No presente trabalho foi relatado um raro caso de PPP, em criança de 6 anos, destacando seu manejo hospitalar e atentando para sua dificuldade diagnóstica. Conclusão: o diagnó

APA, Harvard, Vancouver, ISO, and other styles

8

Marovt, Maruška, and Pij B. Marko. "Apremilast monotherapy for palmoplantar pustulosis: Report of three cases." SAGE Open Medical Case Reports 9 (January 2021): 2050313X2110349. http://dx.doi.org/10.1177/2050313x211034926.

Full text

Abstract:

Palmoplantar pustulosis or palmoplantar pustular psoriasis is chronic skin conditions, characterised by eruptions of sterile pustules on an erythematosquamous background. High-quality data on the treatment of palmoplantar pustulosis are limited, and none is accepted as being effective in general. Apremilast is a small molecule inhibitor of phosphodiesterase 4 approved for the treatment of plaque psoriasis and psoriatic arthritis. We report three cases of palmoplantar pustulosis treated with apremilast monotherapy. Our three cases, as well as previous reports, demonstrate the potential for apre

APA, Harvard, Vancouver, ISO, and other styles

9

Dulski, Anne, and Vince Varamo. "Palmoplantar Pustulosis: A Case Report." Clinical Practice and Cases in Emergency Medicine 4, no. 4 (2020): 664–67. http://dx.doi.org/10.5811/cpcem.2020.7.48476.

Full text

Abstract:

Introduction: Dermatology complaints account for 3.3% of emergency department (ED) visits per year. Most rashes are benign, but there are a select few that emergency physicians must be familiar with as delay in treatment could be life threatening. Case Report: A well-appearing, 76-year-old male presented to the ED with multiple coalescing pustules to his palms and soles and was transferred to the nearest tertiary care hospital for dermatology consult. He was diagnosed with palmoplantar pustulosis and discharged home with a five-day course of clobetasol propionate 0.05% cream twice daily and ou

APA, Harvard, Vancouver, ISO, and other styles

10

Karadaglić, Đorđije, and Silvija Brkić. "Palmoplantar pustulosis – is there any progress in the treatment? / Palmoplantarna pustuloza – ima li pomaka u lečenju?" Serbian Journal of Dermatology and Venerology 3, no. 3 (2011): 101–8. http://dx.doi.org/10.2478/v10249-011-0041-9.

Full text

Abstract:

Abstract Despite, the fact that palmoplantar pustulosis is still widely known by this name, it is currently regarded as a disease distinct from psoriasis. The real cause is still unknown. Septic foci have been blamed, but their removal may not cure eruptions. A case series of de novo occurrence of palmoplantar pustulosis induced by tumor necrosis factor-alpha antagonist therapy has been reported. It has been shown that stress may be related to exacerbation of palmoplantar pustulosis. Some authors suggest that palmoplantar pustulosis is an autoimmune disease. In sera of patients with palmoplant

APA, Harvard, Vancouver, ISO, and other styles

11

Masuda‐Kuroki, Kana, Masamoto Murakami, Naohito Tokunaga, et al. "The microbiome of the “sterile” pustules in palmoplantar pustulosis." Experimental Dermatology 27, no. 12 (2018): 1372–77. http://dx.doi.org/10.1111/exd.13791.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Mizawa, Megumi, Teruhiko Makino, Chieko Inami, and Tadamichi Shimizu. "Jumihaidokuto (Shi-Wei-Ba-Du-Tang), a Kampo Formula, Decreases the Disease Activity of Palmoplantar Pustulosis." Dermatology Research and Practice 2016 (2016): 1–4. http://dx.doi.org/10.1155/2016/4060673.

Full text

Abstract:

Palmoplantar pustulosis (PPP) is a chronic skin disease characterized by sterile intraepidermal pustules associated with erythematous scaling on the palms and soles. Jumihaidokuto is a traditional herbal medicine composed of ten medical plants and has been given to patients with suppurative skin disease in Japan. This study investigated the effect of jumihaidokuto on the disease activity in PPP patients (n=10). PPP patients were given jumihaidokuto (EKT-6; 6.0 g per day) for 4 to 8 weeks in addition to their prescribed medications. The results showed that the palmoplantar pustular psoriasis ar

APA, Harvard, Vancouver, ISO, and other styles

13

Kucera, Kristine J., and Judi Elizabeth Miller. "Treatment of Palmoplantar Pustulosis Using Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion: A Case Report." Journal of Psoriasis and Psoriatic Arthritis 5, no. 4 (2020): 164–67. http://dx.doi.org/10.1177/2475530320950290.

Full text

Abstract:

Background: Psoriasis is a chronic inflammatory disease that affects skin and joints and is associated with numerous comorbidities. There are several clinical subtypes including the uncommon pustular variants, which are subdivided into generalized and localized forms. Palmoplantar pustulosis is considered a subtype of pustular psoriasis that manifests as localized eruptions of pustules affecting the palms and/or soles. The disease often persists for several years or decades, with frequent periods of exacerbation and partial remissions and may significantly impair quality of life secondary to p

APA, Harvard, Vancouver, ISO, and other styles

14

Guenther, Lyn C. "Alefacept is Safe and Efficacious in the Treatment of Palmar Plantar Pustulosis." Journal of Cutaneous Medicine and Surgery 11, no. 6 (2007): 202–5. http://dx.doi.org/10.2310/7750.2007.00036.

Full text

Abstract:

Background: Alefacept blocks T-cell activation and induces apoptosis of memory T cells. It improves psoriasis vulgaris and may induce prolonged remissions. Experience with alefacept in palmar plantar pustulosis (PPP) is limited. Objective: The objective of the study was to observe the effectiveness and safety of alefacept in the treatment of PPP. Methods: Alefacept was administered weekly for 16 weeks by intramuscular (IM) injection of 15 mg to 15 patients with moderate to very severe PPP. Patients were followed for an additional 12 weeks. Results: Four weeks after 16 weeks of treatment, there

APA, Harvard, Vancouver, ISO, and other styles

15

Sánchez, Martín Debén, and Dorotea Ledesma Mateos. "Pustulosis palmoplantar." FMC - Formación Médica Continuada en Atención Primaria 21, no. 4 (2014): 243–44. http://dx.doi.org/10.1016/s1134-2072(14)70750-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Wetter, D. A. "Palmoplantar pustulosis." Canadian Medical Association Journal 185, no. 11 (2012): 982. http://dx.doi.org/10.1503/cmaj.121143.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Cardona Hernández, Miguel Ángel, María del Carmen Padilla Desgarennes, César Alfonso Maldonado García, José Alberto Ramos Garibay, and José Pablo Laguna Meraz. "Pustulosis palmoplantar." Revista del Centro Dermatológico Pascua 30, no. 1 (2021): 29–33. http://dx.doi.org/10.35366/100589.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Masuda, K., M. Murakami, N. Tokunaga, et al. "390 The micribome exists in the 'sterile' pustule of palmoplantar pustulosis." Journal of Investigative Dermatology 138, no. 5 (2018): S66. http://dx.doi.org/10.1016/j.jid.2018.03.397.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

BURGE, S. M., and T. J. RYAN. "Acute palmoplantar pustulosis." British Journal of Dermatology 113, no. 1 (1985): 77–83. http://dx.doi.org/10.1111/j.1365-2133.1985.tb02046.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Klemm, Philipp, and Uwe Lange. "SAPHO-Syndrom." Zeitschrift für Rheumatologie 80, no. 5 (2021): 456–66. http://dx.doi.org/10.1007/s00393-021-00979-4.

Full text

Abstract:

ZusammenfassungBeim SAPHO-Syndrom handelt es sich nicht um eine Entität, sondern um einen inhomogenen, nosologisch wie pathogenetisch heterogenen Symptomenkomplex. Klinisch imponieren subakute, rezidivierende und/oder chronische Krankheitsprozesse mit charakteristisch gemeinsamer Haut-Knochen-Assoziation („ski[n]bo[ne]-disease“). Die chronisch rekurrierende multifokale Osteomyelitis (CRMO) ist die häufigste „SAPHO“-Erkrankung im Jugend- und Adoleszentenalter. Im Erwachsenenalter ist die Spondarthritis hyperostotica pustulo-psoriatica mit der Trias palmoplantare Pustulose, sternokostoklavikulär

APA, Harvard, Vancouver, ISO, and other styles

21

Yamamoto, T. "Extra-palmoplantar lesions associated with palmoplantar pustulosis." Journal of the European Academy of Dermatology and Venereology 23, no. 11 (2009): 1227–32. http://dx.doi.org/10.1111/j.1468-3083.2009.03296.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Murakami, Masamoto, Takaaki Ohtake, Yoshimune Horibe, et al. "Acrosyringium Is the Main Site of the Vesicle/Pustule Formation in Palmoplantar Pustulosis." Journal of Investigative Dermatology 130, no. 8 (2010): 2010–16. http://dx.doi.org/10.1038/jid.2010.87.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Chalmers, Robert. "Management of palmoplantar pustulosis." Clinical and Experimental Dermatology 27, no. 4 (2002): 328–37. http://dx.doi.org/10.1046/j.1365-2230.2002.10433.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

O'Doherty, C. J., and C. MacIntyre. "Palmoplantar pustulosis and smoking." BMJ 291, no. 6499 (1985): 861–64. http://dx.doi.org/10.1136/bmj.291.6499.861.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Cox, N. H., and S. Ray. "Palmoplantar pustulosis and smoking." BMJ 291, no. 6504 (1985): 1278–79. http://dx.doi.org/10.1136/bmj.291.6504.1278-b.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Sudan, B. J. L. "Palmoplantar pustulosis and smoking." BMJ 291, no. 6504 (1985): 1279. http://dx.doi.org/10.1136/bmj.291.6504.1279.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Reitamo, Sakari, Pekka Erkko, and Anita Remitz. "Cyclosporin for palmoplantar pustulosis." Journal of Autoimmunity 5 (April 1992): 285–87. http://dx.doi.org/10.1016/0896-8411(92)90045-r.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Silva, Patricia Craveiro Gomes da, Elisa Fontenelle de Oliveira, Andréa Valentim Goldenzon, Pâmela Craveiro Gomes da Silva, and Marta Cristine Felix Rodrigues. "Desafios no diagnóstico e tratamento de um caso de síndrome SAPHO na infância." Anais Brasileiros de Dermatologia 86, no. 4 suppl 1 (2011): 46–49. http://dx.doi.org/10.1590/s0365-05962011000700011.

Full text

Abstract:

Os autores relatam um caso clínico sobre Síndrome SAPHO, na faixa etária pediátrica, com enfoque dermatológico. Essa entidade deve ser considerada, nos pacientes que tenham dor na parede torácica anterior ou outros sintomas musculoesqueléticos, acompanhados por lesões dermatológicas, como pustulose palmoplantar e acne fulminans. As manifestações cutâneas específicas, diagnóstico e o tratamento utilizado serão apresentados

APA, Harvard, Vancouver, ISO, and other styles

29

Campoy Sánchez, Antonio. "Tratamiento de la psoriasis pustulosa palmoplantar." Piel 17, no. 10 (2002): 500–503. http://dx.doi.org/10.1016/s0213-9251(02)72648-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Yamamoto, Toshiyuki, and Kiyoshi Nishioka. "Severe Extra-Palmoplantar Pustulation Associated with Palmoplantar Pustulosis." Journal of Dermatology 31, no. 8 (2004): 690–92. http://dx.doi.org/10.1111/j.1346-8138.2004.tb00579.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

AGNER, T., J. H. SINDRUP, MIMI HoIER-MADSEN, and L. HEGEDUS. "Thyroid disease in pustulosis palmoplantaris." British Journal of Dermatology 121, no. 4 (1989): 487–91. http://dx.doi.org/10.1111/j.1365-2133.1989.tb15516.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Obermeyer, L., C. Skudlik, S. M. John, and R. Brans. "Berufsdermatologische Aspekte der Pustulosis palmoplantaris." Der Hautarzt 71, no. 9 (2020): 699–704. http://dx.doi.org/10.1007/s00105-020-04611-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Oda, Aya, Keita Yoshida, Tamayo Uno, Taiga Yoshinaka, Akari Mukai, and Masahiro Irifune. "A Case With Deteriorating Palmoplantar Pustulosis and Hyperthyroidism After Simultaneous Bimaxillary Orthognathic Surgery." Anesthesia Progress 64, no. 3 (2017): 173–74. http://dx.doi.org/10.2344/anpr-64-03-03.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Shimizu, Tadamichi, Hironori Niizeki, Osamu Takeuchi, et al. "Induction of macrophage migration inhibitory factor precedes the onset of acute tonsillitis." Mediators of Inflammation 13, no. 4 (2004): 293–95. http://dx.doi.org/10.1080/09629350400003175.

Full text

Abstract:

We investigated the serum macrophage migration inhibitory factor (MIF) levels of palmoplantar pustulosis patients, before and after the tonsillar provocation test. Higher serum MIF levels of palmoplantar pustulosis patients were decreased after the tonsillar provocation test (n=29). To confirm these phenomena, two patients with acute tonsillitis had their changes in body temperature, C-reactive protein (CRP) and serum MIF levels examined during the course of their illness. Surprisingly, increased MIF preceded fever and CRP elevation, and MIF subsequently decreased at the onset of fever and CRP

APA, Harvard, Vancouver, ISO, and other styles

35

Murai, Osamu, Kyosuke Suwabe, Yoshito Ohkawa, Daisuke Sasaki, and Takashi Yaegashi. "Palmoplantar pustulosis and periodontal therapy." Nihon Shishubyo Gakkai Kaishi (Journal of the Japanese Society of Periodontology) 60, no. 3 (2018): 131–38. http://dx.doi.org/10.2329/perio.60.131.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Casals Andreu, Miquel, Miquel Ribera Pibernat, and Jesús Luelmo Aguilar. "Tratamiento de la pustulosis palmoplantar." Piel 25, no. 5 (2010): 275–80. http://dx.doi.org/10.1016/j.piel.2009.12.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Danion, Francois, Erwan Bui, Philippe Riegel, and Bernard Goichot. "Streptobacillosis characterised by palmoplantar pustulosis." Lancet Infectious Diseases 13, no. 1 (2013): 96. http://dx.doi.org/10.1016/s1473-3099(12)70141-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Adişen, E., and M. A. Gürer. "Therapeutic options for palmoplantar pustulosis." Clinical and Experimental Dermatology 35, no. 3 (2010): 219–22. http://dx.doi.org/10.1111/j.1365-2230.2009.03520.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Brunasso, A. M. G., and C. Massone. "Alitretinoin therapy for palmoplantar pustulosis." British Journal of Dermatology 177, no. 2 (2017): 578–79. http://dx.doi.org/10.1111/bjd.15605.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

WENDLING, PATRICE. "Biologic Therapies Tackle Palmoplantar Pustulosis." Family Practice News 35, no. 21 (2005): 32. http://dx.doi.org/10.1016/s0300-7073(05)72066-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Riveiro-Barciela, Mar, Meritxell Ventura-Cots, and Gloria Aparicio. "Palmoplantar pustulosis and chest pain." Lancet 379, no. 9827 (2012): e49. http://dx.doi.org/10.1016/s0140-6736(11)61589-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Shimamura, Yoshinosuke, Takuto Maeda, and Hideki Takizawa. "Palmoplantar pustulosis and IgA nephropathy." Journal of General and Family Medicine 20, no. 1 (2018): 35–36. http://dx.doi.org/10.1002/jgf2.218.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

VERBOV, J. "Arthro-osteitis with palmoplantar pustulosis*." Clinical and Experimental Dermatology 15, no. 5 (1990): 378–79. http://dx.doi.org/10.1111/j.1365-2230.1990.tb02120.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Pyrpasopoulou, Athina, Sofia Chatzimichailidou, Elisavet Simoulidou, and Spyros Aslanidis. "Anti-TNF-Associated Palmoplantar Pustulosis." JCR: Journal of Clinical Rheumatology 16, no. 3 (2010): 138–39. http://dx.doi.org/10.1097/rhu.0b013e3181d59511.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Szanto, E., and U. Linse. "Arthropathy associated with palmoplantar pustulosis." Clinical Rheumatology 10, no. 2 (1991): 130–35. http://dx.doi.org/10.1007/bf02207650.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Karadaglic, Djordjije, and Milica Popovic. "Colchine in dermatology." Vojnosanitetski pregled 60, no. 6 (2003): 715–24. http://dx.doi.org/10.2298/vsp0306715k.

Full text

Abstract:

<zakljucak> Kolhicin je stari lek cija je primena, kao monoterapija ili u kombinaciji sa drugim lekovima, aktuelna i u savremenoj medicini. Najznacajnija mu je primena za lecenje i profilaksu perzistentne palmoplantarne pustuloze i oralnih aftoznih ulceracija, lecenje Svitovog sindroma, Beh?etove bolesti, sklerodermije i fibromatoze penisa.

APA, Harvard, Vancouver, ISO, and other styles

47

Kühn, Fehr, and Stoll. "Junge Frau mit Rückenschmerzen und Akne: SAPHO-Syndrom (Synovitis, Akne, Pustulose, Hyperostose und Osteitis)." Praxis 96, no. 15 (2007): 591–95. http://dx.doi.org/10.1024/1661-8157.96.15.591.

Full text

Abstract:

Wir stellen eine junge, bislang gesunde Frau vor, die an einem SAPHO-Syndrom mit Rückenschmerzen und sternoklavikularen Gelenksbeschwerden erkrankte. Es handelt sich dabei um ein entzündliches Geschehen des Bewegungsapparates (Synovitis, Osteitis und Hyperostose) in Assoziation mit einer schwereren Akne oder einer palmoplantaren Pustulose. Die Behandlung umfasste bei dieser Patientin Pamidronat per infusionem, NSAR und physiotherapeutische Massnahmen und führte zu Beschwerdefreiheit am Bewegungsapparat. Die Akne wurde mit Isotretinoin stark gebessert.

APA, Harvard, Vancouver, ISO, and other styles

48

Dorton, David W. "Palmoplantar Pustules in an Infant." Archives of Dermatology 132, no. 11 (1996): 1367. http://dx.doi.org/10.1001/archderm.1996.03890350109018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

HOSHINO, TAKASHI, and MANABU MINAKAMI. "Rheumatoid Arthritis Associated with Pustulosis Palmoplantaris." Clinical Orthopaedics and Related Research &NA;, no. 216 (1987): 270???275. http://dx.doi.org/10.1097/00003086-198703000-00041.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Sondermann, Wiebke. "Pustulosis palmoplantaris: Langfriste Kontrolle im Blick." Kompass Dermatologie 9, no. 2 (2021): 82–84. http://dx.doi.org/10.1159/000515961.

Full text

Abstract:

Im Rahmen der sog. 2PRECISE-Studie, einer multizentrischen, randomisierten, doppelblinden Phase 3b Parallel-Studie, wurden Patienten mit mittelschwerer bis schwerer PPP (palmoplantarer Psoriasis Area and Severity Index (PPPASI) ≥12 und Dermatology Life Quality Index (DLQI) ≥10) über 52 Wochen mit Secukinumab bzw. Placebo behandelt. Der primäre Endpunkt der Studie war die Bestimmung der Rate der Patienten mit einem ppPASI75 unter Therapie mit Secukinumab in Woche 16 gegenüber Placebo. Es wurde ein Signifikanzlevel von 2,5% zugrunde gelegt. 79 Patienten erhielten Secukinumab in einer Dosierung v

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!